angiogenesis inhibitor

(redirected from Anti-angiogenic)
Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Anti-angiogenic: antiangiogenesis factor, Tumor Angiogenesis Factor

inhibitor

 [in-hib´ĭ-tor]
1. any substance that interferes with a chemical reaction, growth, or other biologic activity.
2. a chemical substance that inhibits or checks the action of a tissue organizer or the growth of microorganisms.
3. an effector that reduces the catalytic activity of an enzyme.
ACE i's (angiotensin-converting enzyme i's) see angiotensin-converting enzyme inhibitors.
angiogenesis inhibitor a group of drugs that prevent growth of new blood vessels into a solid tumor.
aromatase i's a class of drugs that inhibit aromatase activity and thus block production of estrogens; used to treat breast cancer and endometriosis.
C1 inhibitor (C1 INH) a member of the serpin group, an inhibitor of C1, the initial component activated in the classical complement pathway. Deficiency of or defect in the protein causes hereditary angioedema.
carbonic anhydrase inhibitor an agent that inhibits the enzyme carbonic anhydrase; used in treatment of glaucoma and sometimes for epilepsy, familial periodic paralysis, acute mountain sickness, and kidney stones of uric acid.
cholinesterase inhibitor anticholinesterase.
COX-2 i's (cyclooxygenase-2 i's) a group of nonsteroidal antiinflammatory drugs that act by inhibiting cyclooxygenase-2 activity; they have fewer gastrointestinal side effects than other NSAIDs. Two members of the group are celecoxib and rofecoxib.
gastric acid pump inhibitor an agent that inhibits gastric acid secretion by blocking the action of H+,K+-ATPase at the secretory surface of gastric parietal cells; called also proton pump i.
HIV protease inhibitor any of a group of antiretroviral drugs active against the human immunodeficiency virus; they prevent protease-mediated cleavage of viral polyproteins, causing production of immature viral particles that are noninfective. Examples include indinavir sulfate, nelfinavir mesylate, ritonavir, and saquinavir.
HMG-CoA reductase i's a group of drugs that competitively inhibit the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, and are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia. Called also statins.
membrane inhibitor of reactive lysis (MIRL) protectin.
monoamine oxidase inhibitor any of a group of drugs that inhibit the action of monoamine oxidase, the enzyme that breaks down norepinephrine and serotonin, prescribed for their antidepressant action; the most widely used ones are isocarboxazid, phenelzine, and tranylcypromine. They are also used in the prevention of migraine.
α2-plasmin inhibitor α2-antiplasmin.
plasminogen activator inhibitor (PAI) any of several regulators of the fibrinolytic system that act by binding to and inhibiting free plasminogen activator. Their concentration in plasma is normally low, but is altered in some disturbances of bodily hemostasis. PAI-1 is an important fast-reacting inhibitor of t-plasminogen activator and u-plasminogen activator. Its synthesis, activity, and release are highly regulated; elevated levels of it have been described in a number of disease states. PAI-2 is a normally minor inhibitor that greatly increases in concentration during pregnancy and in certain disorders. PAI-3 is protein C inhibitor.
platelet inhibitor any of a group of agents that inhibit the clotting activity of platelets; the most common ones are aspirin and dipyridamole. See also antiplatelet therapy.
protease inhibitor
1. a substance that blocks activity of endopeptidase (protease), such as in a virus.
protein C inhibitor the primary inhibitor of activated anticoagulant protein C; it is a glycoprotein of the serpin family of proteinase inhibitors and also inhibits several other proteins involved in coagulation (thrombin, kallikrein, and coagulation factors X and XI) and urokinase. Called also plasminogen activator inhibitor 3.
proton pump inhibitor gastric acid pump i.
reverse transcriptase inhibitor a substance that blocks activity of the reverse transcriptase of a retrovirus and is used as an antiretroviral agent. Some are nucleosides or nucleoside analogues, and those that are not are therefore often called non-nucleoside reverse transcriptase inhibitors.
selective serotonin reuptake inhibitor (SSRI) any of a group of drugs that inhibit the inactivation of serotonin by blocking its absorption in the central nervous system; used as antidepressants and in the treatment of obsessive-compulsive disorder and panic disorder.
serine protease inhibitor (serine proteinase inhibitor) serpin.
topoisomerase i's a class of antineoplastic agents that interfere with the arrangement of DNA in cells.

angiogenesis inhibitor

n.
A drug that blocks angiogenesis in cancerous tissue, thus interfering with tumor growth or metastasis.

angiogenesis inhibitor

one of a group of drugs that prevent the growth of new blood vessels into a solid tumor.

angiogenesis inhibitor

A chemotherapy adjuvant (e.g., TNP-470, Avastin) that inhibits the angiogenesis required for tumour growth and survival, especially for metastastatic tumours.

angiogenesis inhibitor

Oncology A chemotherapy adjuvant which inhibits the angiogenesis required for tumor growth and survive, especially for metastastatic tumors See CAI, CM101, IFN-alpha, IL-12, Marimastat, Pentosan polysulfate, Platelet factor 4, Thalidomide, TNP-470.

angiogenesis inhibitor

One of a range of substances that block the development of new blood vessels (angiogenesis) and show promise as anticancer drugs. Cancers cannot grow beyond microscopic size unless they develop new blood vessels. If this is prevented they will regress or remain dormant and harmless. Research has shown that the angiogenesis inhibitors endostatin and angiostatin are capable of eliminating cancers of the breast, colon, prostate and brain in mice and can do so without undesirable side effects in the short term. These two drugs act in different ways and research on humans with cancer was started in mid-1998. The drugs are believed not to induce drug resistance in mice.
References in periodicals archive ?
For practical applications for cancer patients, normal tissues instead of tumor cells could be genetically modified to produce the anti-angiogenic proteins.
It is generally recognized by the scientific community that an anti-angiogenic therapy holds great promise for treating AMD.
Table 56: Anti-angiogenic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
The first of the three presentations, "Palomid 529, a Dual Acting Anti-angiogenic and Direct Anti-tumor Agent Affecting the PI3K/Akt/mTor Pathway," was be given by Dr.
The data on unlabeled TM601 reveals that vascular perfusion is potentially a biomarker for TM601 treatment response, and the activity seen in this study is consistent with the unique anti-angiogenic activity of the compound, which we reported at a recent medical meeting.
These studies provided new insight in understanding mechanisms of tumor progression and metastasis, leading to the identification of protein targets and agents with potent anti-angiogenic activities," said Zhican Qu, Ph.
Poster presentation #2041 is titled, "A Phase 1 evaluation of intravenous TM601 in recurrent glioblastoma: use of perfusion MRI to monitor anti-angiogenic effects," and will be presented on Sunday, May 31, in the Central Nervous System Tumors General Poster Session from 8:00 am - noon ET (Level 2, West Hall C).
today presented preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting demonstrating new information on the anti-angiogenic mechanism-of-action of TM601.
announced that its mda-7 based cancer drug, INGN 241, demonstrated potent anti-angiogenic properties in a preclinical study recently presented during the annual meeting of the American Society of Gene Therapy.
today announced that new information on the anti-angiogenic method-of-action of TM601 will be presented in a poster session at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, FL, being held May 3-7, 2009.
Late-breaking advances in anti-cancer research on novel protein kinase, metalloproteinase, farnesyl transferase, and anti-angiogenic inhibitors at the pre-clinical and clinical stages will be the focus of a new pharma conference series to take place in Princeton, NJ on June 12-13, 2000, announces Strategic Research Institute.